Hepatitis C Virus Antibody by CIA with Reflex to HCV by Quantitative NAAT
Also known as: HCV AB QR
Use
This test is designed to screen and confirm the presence of Hepatitis C Virus (HCV) infection in individuals at risk. It uses a qualitative chemiluminescent immunoassay (CIA) to detect the presence of HCV antibodies. If these antibodies are detected, the test reflexes to a quantitative nucleic acid amplification test (NAAT) to confirm active infection. The detection of HCV RNA through NAAT indicates viral replication, confirming active HCV infection, which aids in diagnosis and management of patients undergoing antiviral therapy.
Special Instructions
Not provided.
Limitations
The test should not be used for blood donor screening, associated reentry protocols, or for screening human cells, tissues, and tissue-based products. A 'Not Detected' result for HCV RNA does not rule out infection, as it may be below the level of detection or the presence of inhibitors may affect the result. Single measurement of viral load should be interpreted in the context of the patient's clinical and laboratory findings.
FDA ApprovedNew York Approved
Methodology
Immunoassay (CLIA)
Biomarkers
LOINC Codes
- 13955-0 - HCV Ab SerPl Ql IA
- 57006-9 - HCV IgG Ser IA-aCnc
Result Turnaround Time
1-5 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
2.5 mL
Minimum Volume
1.5 mL
Container
ARUP standard transport tube
Collection Instructions
Separate from cells within 6 hours of collection. Transfer serum or plasma to a transport tube dedicated to HCV AB QR testing.
Storage Instructions
Frozen
Causes for Rejection
Heparinized plasma. Specimens containing particulate material. Severely hemolyzed, heat-inactivated, or lipemic specimens.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 24 hours |
| Refrigerated | 6 days |
| Frozen | 2 months |
Other tests from different labs that may be relevant